Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand; Graduate School, Chiang Mai University, Chiang Mai, 50200, Thailand.
Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Chem Biol Interact. 2022 Jan 5;351:109703. doi: 10.1016/j.cbi.2021.109703. Epub 2021 Oct 19.
Agomelatine, a novel antidepressant, is a melatonin MT receptor agonist and serotonin 5HT receptor antagonist. In this study, agomelatine was used to investigate the molecular mechanisms of hippocampal aging associated with endoplasmic reticulum (ER) stress, mitochondrial dysfunction, and apoptosis, all of which led to short-term memory impairment.
Hippocampal aging was induced in male Wistar rats by d-galactose (D-gal) intraperitoneal injection (100 mg/kg) for 14 weeks. During the last 4 weeks of D-gal treatment, rats were treated with agomelatine (40 mg/kg) or melatonin (10 mg/kg). At the end of the experiment, all rats were assessed for short-term memory by using the Morris water maze test. Subsequently, rats were sacrified and the hippocampus was removed from each rat for determination of reactive oxygen species (ROS), malondialdehyde (MDA), and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays; and immunohistochemistry related to ER stress, mitochondrial dysfunction, and apoptosis.
Agomelatine suppressed the expression of the aging-related proteins P16 and receptor for advanced glycation endproducts (RAGE), the expression of NADPH oxidase (NOX) 2 and 4, and ROS production. This treatment also shifted the morphology of astrocytes and microglia toward homeostasis. Furthermore, agomelatine decreased inositol-requiring enzyme 1 (pIRE1), protein kinase R-like endoplasmic reticulum kinase (pPERK), and chaperone binding immunoglobulin protein (BiP), leading to suppression of ER stress markers C/EBP homologous protein (CHOP) and caspase-12. Agomelatine reduced Ca from the ER and stabilized the mitochondrial membrane stability, which was denoted by the BCL2 Associated X (Bax)/B-cell lymphoma 2 (Bcl2) balance. Agomelatine decreased cleaved caspase-3 production and the Terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL)-positive area, and glutamate excitotoxicity was prevented via suppression of N-methyl-d-aspartate (NMDA) receptor subunit expression. Agomelatine exhibited effects that were similar to melatonin.
Agomelatine improved neurodegeneration in a rat model of hippocampal aging by attenuating ROS production, ER stress, mitochondrial dysfunction, excitotoxicity, and apoptosis.
阿戈美拉汀是一种新型抗抑郁药,作为褪黑素 MT 受体激动剂和 5-羟色胺 5HT 受体拮抗剂。在这项研究中,阿戈美拉汀被用于研究与内质网(ER)应激、线粒体功能障碍和细胞凋亡相关的海马体衰老的分子机制,所有这些都会导致短期记忆障碍。
通过腹腔注射 D-半乳糖(D-gal)(100mg/kg)诱导雄性 Wistar 大鼠海马体衰老,共 14 周。在 D-gal 处理的最后 4 周,大鼠用阿戈美拉汀(40mg/kg)或褪黑素(10mg/kg)处理。实验结束时,所有大鼠均通过 Morris 水迷宫测试评估短期记忆。随后处死大鼠,从每只大鼠中取出海马体,进行活性氧(ROS)、丙二醛(MDA)和末端脱氧核苷酸转移酶 dUTP 缺口末端标记(TUNEL)测定;以及与 ER 应激、线粒体功能障碍和细胞凋亡相关的免疫组织化学检测。
阿戈美拉汀抑制了衰老相关蛋白 P16 和晚期糖基化终产物受体(RAGE)、NADPH 氧化酶(NOX)2 和 4 以及 ROS 产生的表达。这种治疗还使星形胶质细胞和小胶质细胞的形态向稳态转变。此外,阿戈美拉汀降低了肌醇需求酶 1(pIRE1)、蛋白激酶 R 样内质网激酶(pPERK)和伴侣结合免疫球蛋白蛋白(BiP)的表达,从而抑制了 ER 应激标志物 C/EBP 同源蛋白(CHOP)和半胱天冬酶-12 的表达。阿戈美拉汀减少了 ER 中的 Ca2+并稳定了线粒体膜的稳定性,这表现在 BCL2 相关 X(Bax)/B 细胞淋巴瘤 2(Bcl2)的平衡上。阿戈美拉汀减少了 cleaved caspase-3 的产生和末端脱氧核苷酸转移酶生物素-dUTP 缺口末端标记(TUNEL)阳性面积,并通过抑制 N-甲基-D-天冬氨酸(NMDA)受体亚基的表达来防止谷氨酸兴奋性毒性。阿戈美拉汀的作用与褪黑素相似。
阿戈美拉汀通过抑制 ROS 产生、ER 应激、线粒体功能障碍、兴奋性毒性和细胞凋亡,改善了大鼠海马体衰老模型中的神经退行性变。